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The gold standard in the repair of bony defects is autologous bone grafting, even though it has drawbacks in terms of availability
andmorbidity at the harvesting site. Bone-tissue engineering, in which osteogenic cells and scaffolds are combined, is considered as
a potential bone graft substitute strategy. Proof-of-principle for bone tissue engineering using mesenchymal stromal cells (MSCs)
has been demonstrated in various animal models. In addition, 7 human clinical studies have so far been conducted. Because the
experimental design and evaluation parameters of the studies are rather heterogeneous, it is difficult to draw conclusive evidence
on the performance of one approach over the other. However, it seems that bone apposition by the grafted MSCs in these studies is
observed but not sufficient to bridge large bone defects. In this paper, we discuss the published human clinical studies performed
so far for bone-tissue regeneration, using culture-expanded, nongenetically modified MSCs from various sources and extract from
it points of consideration for future clinical studies.
1. Introduction
Bone lesions/defects caused by, for example, trauma, bone
resection due to ablative surgery, or correction of congenital
deformities are a common problem in clinical practice. In
the majority of the cases, the body’s self-healing capacity is
able to repair the defect. Yet every year, in roughly 1 million
cases of skeletal injury, the defect size is too big or conditions
not optimal to allow healing (Figures 1 and 2). In these cases,
external help is required in the form of bone graft procedures
to achieve union [1].
The most frequently used sources of bone grafting are
autologous and allogeneic bone [2]. Autologous cancellous
bone grafts are most successful in the present clinical
scenario, because in addition to being osteoconductive and
osteoinductive, they are safe, cheap, and easily available to
the surgeons. However, obtaining autologous grafts requires
the patient to be subjected to additional surgery, thus
introducing extra morbidity at the donor site and increasing
surgical costs [3–5]. Besides, the amount of graft material
is limited and chances of complications such as infections,
instability, and paraesthesia at the donor site can affect
up to 30% of patients [6–8]. An alternative is allogeneic
bone grafting, which can be obtained from authorized tissue
banks which collect and store bone tissues from human
cadavers [7]. By this approach, problems associated with
harvesting and quantity of graft material are bypassed.
To avoid problems associated with immunogenicity, donor
grafts can be devitalized via processes such as irradiation and
freeze drying. Unfortunately, this processing also eliminates
the cellular component, thus reducing the graft’s osteoin-
ductivity, thereby resulting in a slower rate of new bone
formation as compared to autologous grafts [9].
As an alternative to autologous or allogeneic bone grafts,
surgeons may use scaffolds made of synthetic or natural
biomaterials that promote the migration, proliferation, and
2 Stem Cells International
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Figure 1: 3D reconstruction of a skull and mandibular defect in trauma patients. Surgeons are often faced with patients having large defects
in the bone which do not heal spontaneously. The gaping hole in the skull and the area highlighted in red in the mandible are examples
of large-sized defects in real patients. Though autografts are the gold standard treatment for such patients, the amount of graft material
required is often the limiting factor. Tissue regeneration using synthetic or natural scaffolds seeded with mesenchymal stem cells can be an
alternative solution for such patients.
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Figure 2: Mandibular defect following cyst. CT scan of huge cyst in the mandible (see white arrows). The clinical picture represents the
situation after removing the cyst revealing the alveolar nerve positioned at the bottom of the cavity (black arrow).
differentiation of bone cells. In the last decade, a large
number of publications have illustrated the osteoinductive
and osteoconductive properties of scaffolds such as synthetic
hydroxyapatite (HA) [10–12], coralline HA [13–15], β-
Tricalcium phosphate and porous biphasic calcium phos-
phate [16–19], calcium phosphate cements [20], chemically
treated titanium [21], and glass ceramics [22]. However, the
degree of osteogenic and osteoinductive properties provided
by the osteoprogenitor cells, as present in the autografts,
exceeds that of the scaffolds. To improve osteoinductivity,
scaffold materials can be loaded with osteoinductive growth
factors such as bone morphogenetic proteins (BMPs).
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The drawback of the growth factor approach are the
supraphysiological concentrations needed to obtain the
desired osteoinductive effects, their high costs, and more
importantly, potential ectopic bone formation [23, 24].
Alternatively, scaffolds can be loaded with osteoprogen-
itor cells in order to generate a living bone graft in vitro,
an approach referred to as bone-tissue engineering. Various
possible sources for osteoprogenitor cells have been consid-
ered. Osteoblasts obtained from autologous bone biopsies
and then expanded in vitro were an obvious first choice
due to their nonimmunogenicity. However, the relatively low
number of cells obtained after dissociation of the biopsy
specimen, the time-consuming nature of the whole process
and the problems associated with obtaining osteoblasts from
patients with bone-related diseases prompted continuation
of the search for better options [1, 25]. Mesenchymal
stromal or stem cells (MSCs) which can be obtained from
various tissue sources, like bone marrow, adipose tissue,
umbilical cord, or placenta provide an alternative source of
osteoprogenitor cells. MSCs were first identified in the bone
marrow by Friedenstein and coworkers in 1966 [26] and
were subsequently named mesenchymal stem cell (MSCs)
by Caplan [27]. They are very attractive to researchers
as they can be extensively expanded in vitro to obtain
numbers sufficient to treat large bone defects [28], and they
have immunosuppressive effects in vivo, which may make
them suitable for allogeneic transplantations [29, 30]. MSCs
isolated from different sources share many phenotypical
and functional characteristics. However, depending on the
tissue source and the isolation methods employed, their
differentiation potential varies [31]. The varied tissue sources
and isolation methods make it difficult to determine if the
resulting cells are sufficiently similar to allow for a direct
comparison. Therefore, the International Society for Cellular
Therapy proposed a set of minimal criteria to label a cell
as a MSC [32]. These include: (1) cells must be plastic
adherent when maintained in standard culture conditions;
(2) they must express CD105, CD73, and CD90 and lack
expression of CD 45, CD34, CD14, or CD11b, CD79α or
CD 19 and HLA-DR surface molecules; (3) they should
differentiate into osteoblasts, adipocytes, and chondroblasts
in vitro. Haynesworth et al. were the first to combine human
MSCs from adult bone marrow with ceramic scaffolds to
successfully generate bone in vivo upon ectopic implantation
into immunodeficient mice [33]. This provided proof-of-
principle on the feasibility of using hMSCs in bone-tissue
engineering. Since then a lot of interest has been generated in
the field of tissue engineering, resulting in in vitro and in vivo
studies with different scaffold/cell combinations. The proof
of concept for repair of critically sized bone defects using
tissue-engineered bone graft substitutes has been provided
by a number of animal studies [30, 34–44], and several
clinical studies have been conducted to assess the safety and
efficacy of this approach in man. Nevertheless, bone-tissue
engineering did not find its way to routine clinical practice.
Here, we present an overview of all published human
clinical studies performed so far to generate bone using
constructs seeded with culture expanded, autologous, non-
genetically modified MSCs obtained from various human
cell sources, suggest possible recommendations for future
design of clinical studies, and describe future research
directions. Cells from the periosteum have not been included
in this paper because no studies have been performed to
determine the MSC nature of the periosteal cells used in the
clinical studies. There are previous reports which indicate
that the periosteal cells fulfill the minimal criteria to be
labeled as an MSC [45–48]. However, there are differences
in the isolation and expansion protocols used in these studies
and in the studies employing the cells for clinical applications
[49–52]. Studies using the mononuclear fraction of the bone
marrow or adipose tissue have also been excluded from
this paper. Although MSCs are present in the mononuclear
fraction, other populations of cells also form a large part of
this fraction.
2. Clinical Studies in Humans Using
Autologous MSCs from Various Cell Sources
for Bone Tissue Engineering
Prior to market release of tissue-engineered products, an
investigational new drug application (NDA) may have to be
submitted to accredited regulatory bodies such as the Food
and Drug Administration (FDA) or the European Medicines
Agency (EMEA). Following this, clinical trials have to be
enrolled as phase 1, phase 2, or phase 3 trials. In phase
1, evidence is obtained about the safety of a particular
approach in a selected group of patients. Generally, these
are small trials with a number of patients recruited being
less than 30. In phase 2, more patients are included to
evaluate effectiveness on the possible applications. Phase 3
clinical trials involve multicentre trials on 300–3000 patients
and are a definitive assessment of the concerned treatment
in comparison with the current gold standard. Following
completion of all phases of clinical trials, the regulatory
body reviews the results, before making a final decision
on the release of the tissue engineered product in the
market. A search on clinicaltrials.gov using search terms,
“Mesenchymal stromal cells”, “autologous MSCs,” and “bone
tissue engineering”, provided 2 relevant studies.
(1) “Treatment of osteonecrosis of the femoral head with
implantation of autologous bonemarrow cells, a pilot
study.”
This is a phase 1 study, which started in January 1999
and was completed in September 2008. However, no
publications describing the study results are currently
available in literature.
(2) “Autologous implantation of Mesenchymal stem cells
for the treatment of distal tibial fractures”. This is an
ongoing, phase 1/phase 2 study. The study started in
April 2009 and the expected primary completion date
is April 2011. No results from this study have yet been
published in the literature
Designs of clinical trials vary from randomized control
trials (RCT), replicated single subject experiments, cohort
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outcome studies, systematic case studies, and case reports.
In general, the more rigorous the design of a clinical trial,
the greater the credibility that can be attached to the
conclusions derived from the outcome of a study. Based
on the methodological rigour applied, RCTs are generally
considered at the top of the hierarchy as randomization in
selection of patients for inclusion in the various treatment
groups ensures negation of the selection bias while inclusion
of controls help rule out the effects of the confounding
factors that may have an effect on the treatment outcome.
However, due to practical and ethical issues involved in
conducting RCTs, most of the trials conducted on human
patients and described in literature for bone-tissue engineer-
ing are at the level of cohort outcome studies or case reports.
Cohort studies provide information on the percentage of
patients which respond positively to a given therapeutic
technique while case reports describe the effects of using
a particular tissue-engineered graft in a single patient.
The observed results in the latter can be thus idiosyncratic
to the specific patient being evaluated and systematic
replications of the experiment would be necessary prior to
obtaining conclusive evidence. Absence of controls in cohort
studies is a major drawback of such a study design. However,
these preliminary attempts also have an important role in
the development of scientific research because they generate
information that can provide some clues to the safety and
potential therapeutic effects of the treatment option andmay
stimulate researchers to perform the more elaborate, time
consuming, and costly RCTs in the future. In this paper,
we list all human clinical studies, including case reports
that have been published in literature, using autologous,
culture expanded, nongenetically modified, human MSCs
for purpose of bone tissue engineering. None of these studies
have obtained approval from institutions such as FDA or
EMEA. The ethical approval for conducting these studies has
been provided by their respective local university/hospital
ethics committees.
The first clinical case series demonstrating feasibility of
using tissue-engineered constructs (TEC), as an alternative
to autologous bone grafts for treating long bone defects, was
reported by Quarto et al. [53]. In 2001, they described the
preliminary results of 3 patients (27, 16, and 15 months
respectively postsurgery) suffering from various segmen-
tal defects (Figure 3). The patients were chosen because
conventional surgical therapies such as Ilizarov’s technique
which excludes graft transplant, had failed. The Ilizarov’s
technique relies on the bone regeneration potential to fill
the gap created artificially via osteotomy of the affected
segment while maintaining the periosteum intact and then
distraction of the two separated halves fixed apart used
ring fixators [54]. Autografts were technically difficult to
perform because the degree of bone loss would leave the
patient with serious donor site morbidity. The first patient
was a 41-year-old female with a 4 cm large segmental bone
defect in the right tibia, the second a 16-year-old female
suffering from a traumatic loss of a 4 cm segment of the distal
diaphysis of the right ulna, while patient 3 was a 22-year-
old male, who missed a 7 cm segment of the right humerus.
For all the patients, macroporous 100% hydroxyapatite (HA)
(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Figure 3: Radiographs obtained before and after the repair of large
bone defects in three Patients from the study by Quarto et al. panels
(a)–(c) show films obtained from Patient 1 before, immediately
after, and 18 months after surgery, respectively. Panels (d)–(f) show
films from Patient 2 before, immediately after, and eight months
after surgery, respectively. Panels (g)–(i) show films from Patient 3
before, immediately after, and 15 months after surgery, respectively.
All the films obtained at the last time point demonstrate bridging of
the defect with newly formed bone.
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scaffolds were custom made to fit the shape and size of the
defect. These were then loaded with ex vivo expanded hMSCs
isolated from their own bone marrow. All 3 patients were
monitored with radiographs and CT scans, which revealed
abundant callus formation by the second month postsurgery
and good integration of the implants with peri-implant bone
formation by the sixth month after surgery. A followup
report 6-7 years after surgery reported that the implants
displayed good osseointegration with no further compli-
cations. Angiographic evaluation performed in patient 3,
6.5 years after surgery also indicated vascularization of the
grafted zone suggesting presence of vital bone at the graft site.
However, no controls were included in this study, and initial
followupwas based only on radiological evaluation which the
authors admit was not optimal because the highmineral den-
sity of the scaffolds used made it difficult to differentiate the
new bone from the preexisting scaffold [55]. Nevertheless,
the study showed that the procedure is safe to perform.
In the years after the initial trial, case studies involving
single patients treated with tissue-engineered constructs
were reported in the literature. In 2007, Krecic Stres et al.
treated 1 patient with a comminuted fracture femur using
a combination of TEC and autologous cancellous bone in
a ratio of 2 : 1 [56]. The TEC was generated by seeding
bonemarrow derivedMSCs on porous calcium-triphosphate
granules. Clinically, the researchers claim that the patient
has been recovering well. However, the combination of
autologous bone with the TEC makes it difficult to draw
conclusive inferences on the feasibility of using TEC alone
for bone-tissue engineering as it would be impossible to
determine the individual contributions of the TEC and the
autologous bone. Moreover, the investigators only relied
on clinical evaluation and X-rays to determine new bone
formation. No controls or biopsies were planned for the
patient. Also, the actual defect size was not mentioned. This
is essential as the size of the graft has been found to be crucial
in determining the survival of the cells within the core of the
graft.
Hibi et al. reconstructed an alveolar cleft defect by
injecting culture expanded and osteogenically-induced bone
marrow derived MSC mixed with autologous platelet rich
plasma [57]. This study provided a novel approach of using
autologous platelet rich plasma as the scaffolding material
for the cells. The patient was followed up postoperatively
with serial CT scans which showed the regenerated bone
extending from the cleft walls after 3 months and bridging
the cleft after 6months. It remains unclear whether the defect
is filled by bone tissues produced by the implanted cells, or
it is formed due to osteoconduction from the border of the
cleft defect.
In 2010, Lee et al. described a successful reconstruction
followed by dental implant placement of a 15 cm jaw defect
as a result of segmental mandibulectomy due to central
hemangioma in a 14-year-old boy [58]. Three reconstructive
surgeries were performed. In the first surgery, autologous
resected mandible obtained during the hemimandibulec-
tomy was used as a tray into which osteogenic-differentiated
autologous bone marrow stem cells and fibrin glue was
injected. Due to lack of adequate mandibular bone for dental
implant placement and recovery of dentition, the second
surgery involved vertical distraction osteogenesis with injec-
tion of autologous osteoblastic-differentiated MSCs. The
third and final surgery was 7 months later for implant
placement. At the time of implant placement biopsies were
taken from the implant site and histological evaluation of the
biopsies revealed newly formed viable lamellar bone. Dental
CT images taken 4 months after the implant placement
confirmed continued presence of mineralized bone at the
augmentation zone.
In 2009, Mesima¨ki et al. reconstructed a major maxil-
lary defect in an adult patient using autologous adipose-
derived MSCs (ASCs) combined with rhBMP-2 and β-TCP
granules in a microvascular reconstruction surgery [59].
After isolating the ASCs from abdominal subcutaneous fat
in autologous serum using GMP class clean room facilities,
the cells were seeded on β-TCP scaffolds. Prior to combining
with cells, the scaffolds were incubated for 48 hours in basal
medium supplemented with rhBMP-2. This medium was
discarded when the cells were added and fresh medium
without rhBMP-2 was added. The cell scaffold combination
was kept in culture for 48 hours prior to their placement
in a titanium cage and subsequent implantation in a pouch
prepared in the patients left rectus abdominus muscle. The
vascular supply of the muscle was not disturbed. 8 months
later, the rectus abdominus muscle pouch was opened, and
the titanium cage filled with the TCP granules and ASCs
was macroscopically examined. The new bone formed in
the cage was clinically confirmed to be vital and rigid. A
biopsy taken from the newly formed bone revealed histology
of normal mature bone. Subsequently, the vessels were
disconnected from the rectus abdominus muscle and the
muscle flap together with the tissue engineered bone was
placed in the maxillary defect. The abdominal vessels were
reanastamosed with the facial vessels. The muscle was left
to epithelialize intraorally. The patient was followed up with
CT scans. Within two months of the surgery, the muscle
flap had almost completely epithelialized, and the shape
and normal bone density was achieved in the reconstructed
maxilla (Figure 4). Four months after placement of the graft,
dental implants were placed and their primary stability
was reported to be excellent. The implants osseointegrated
without any reported adverse effects. This study was the
first clinical case where ectopic bone was produced using
autologous ASCs in a microvascular reconstruction study.
It demonstrated the feasibility and safety of using ASCs for
bone regeneration. However, the relative contribution of the
rhBMP-2 and the ASCs in the new bone formed remains to
be determined.
In 2007, a study was performed by Sbayesteh et al. for
posterior maxillary sinus augmentation involving 6 patients
[60]. In this study, the cell source was the bone marrow
from the iliac crest and the carrier material was hydroxyl
apatite/β-tricalcium phosphate (HA/TCP) particle. After 3
months, biopsies were taken and results showed a mean
bone formation of 41%. Although biopsies were taken, no
information of the bone distribution in the scaffold or the
source of the newly formed bone (donor or recipient) was
provided.
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Figure 4: Twomonths postoperative results of the study byMesimaki et al. Mesimaki et al. reconstructed a major maxillary defect in an adult
patient using autologous adipose-derived MSCs (ASCs) combined with rhBMP-2 and β-TCP granules in a microvascular reconstruction
surgery. Two months postoperative results indicate that (a) the rectus abdominis muscle has atrophied nearly totally and epithelialized
almost completely. Only a small area in the molar region was nonepithelialized. A well-formed buccal sulcus is also noted. Axial (b) and 3D
CT scans (c) show the shape and normal bone density of the new maxilla.
Another clinical study was reported by our group in
order to test the potency of bone-tissue engineering using
bone marrow-derived MSCs seeded onto hydroxyapatite
particles in 6 patients, requiring reconstruction of bony
jaw defects prior to dental implant placement (Figure 5)
[61]. Culture expanded bone marrow-derived MSCs were
seeded on hydroxyapatite particles varying in size from 1–
4mm3. Similar to the work of Schimming et al., the cells
were grown on the scaffolds for another 7 days in order
to allow further osteogenic differentiation and extracellular
matrix deposition and then placed under the mucoperiosteal
flap in the defect site. In this study, both the in vitro
osteogenic capacity and the in vivo bone-forming potential
of the constructs was assessed using representative samples
of cells and constructs, respectively. The in vitro potential
was tested by performing alkaline phosphatase staining,
while the in vivo bone-forming capacity of the constructs
was confirmed by implanting representative constructs,
prepared in an identical fashion to the constructs actually
used for the defects, in subcutaneous locations in nude
mice. Although no quantification of the bone formed
by these hMSCs in the mouse subcutaneous model has
been performed, we noted that all the constructs with
cells implanted in the nude mice showed bone forma-
tion. Four months after application of the construct in
the jaw of the human subjects, and before placement
of the implant, a biopsy was taken from the operation
site. Bone formation was evaluated histologically in the
human patients, and in 3 of them, no new bone for-
mation was observed. Of the remaining 3, in 2 patients
bone tissue in the scaffolds was observed in close contact
with the preexisting bone of the bony defect. This can
likely be attributed to migration of osteoblasts from the
surrounding bone tissue. In only 1 patient, bone forma-
tion was observed more than 7mm from the preexisting
bone tissue. We consider this to be strongly suggestive for
de novo osteogenesis induced by the implanted cells. An
overview of the above mentioned clinical trials are presented
in Table 1.
3. Experimental Design of Clinical Studies
The clinical studies conducted so far have demonstrated that
it is safe to use hMSCs in bone grafting procedures. None of
the reports mention adverse effects such as inflammation or
excessive tissue growth, despite the fact that there are in vitro
studies which suggest that MSCs which have been extensively
cultured (4-5 months) can develop genomic instability,
which can be an indicator of malignant transformation [62–
64]. For most clinical applications, a 6–8-week expansion
phase provides sufficient cell numbers. This may account for
the fact that no malignant potential of the TECs has been
observed in the clinical cases performed so far. However,
to ensure safety for the patient, we propose that in future
clinical studies, chromosomal analysis of implanted cells is
assesed. Secondly, most of the clinical studies published have
a short followup period. We recommend using longer fol-
lowup periods to obtain data on the long term safety of TEC.
The data presented in the clinical studies make it likely
that the grafted hMSCs were able to contribute to bone
regeneration, which provides proof of concept for the
potential use of tissue-engineered grafts in bone regener-
ation. However, the lack of “gold standard” controls and
objective evaluation measures such as bone quantification
using histology makes it difficult to draw strong conclusions.
The studies where biopsies have been used to evaluate
the percentage of bone formed seem to suggest that the
contribution of the grafted cells is very limited and certainly
not sufficient to bridge critical-sized defects. Thus, in order
to be able to normalize the efficacy of a given bone TE
strategy with respect to that of other trials, we recommend
the use of a reference for the bone-forming potential of a
tissue-engineered graft. Given that immune-deficient mice
have been used by many researchers in the field, we would
like to propose that the tissue-engineered grafts to be
implanted in patients will be evaluated inmice in parallel and
bone formation will be quantitatively assessed.
Future studies should attempt to include comparisons
of the TECs with autologous bone grafts for the same
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Table 1: Overview of the clinical studies performed on humans using-tissue engineered constructs.
Principal
investigator
Year
Cell
source
Scaffold Patients
Area of
reconstruction
Salient features Evaluation Reported outcome
R.Quarto 2001
Bone
marrow
100%
hydroxyapatite
3
Long bone
defects (1 tibia,
1 ulna, 1
humerus)
(1) First clinical trial in
humans using hMSCs
(2) Patients with long bone
defects selected
(3) Patients had good
clinical recovery
(3) No side effects even
after 6-7 years followup
Radiology CT
scan
Angiography
No quantification of
new bone formed.
Good integration of
the host bone with
the implanted
scaffolds
H. Hibi 2006
Bone
marrow
Platelet gel 1
Alveolar cleft
defect
(1) First study using
platelet gel as the
scaffolding material
Serial Ct scans
Comparable bone
formation to that
described in
literature with
autolgous bone
grafts
Y.Soleymani 2007
Bone
marrow
HA/TCP 6
Maxillary sinus
augmentation
(1) Good bone formation
in all scaffolds
(2) Mean amount of new
bone regenerated was
41.3%
(3) When compared to the
Vacnati study, stark
difference in the amount fo
bone formed, probably due
to location of defect or cell
source
Radiology
Biopsy
Reported successful
with mean bone
regenerate as
41.34% and good
osseointegration
H.Krecic-
Stres
2007
Bone
marrow
Porous
calcium
triphosphate
granules
1 Femoral defect
(1) autologous bone graft
was mixed with TECs made
with MSCs and scaffolds in
ratio of 1 : 2 to fill the defect
Radiology
Good clinical
recovery. No bone
quantification
performed
Gert Meijer 2008
Bone
marrow
Hydroxyapatite
scaffolds
6
Intraoral
osseous defects
(1) Only study which
performed a biopsy to not
just to quantify the amount
of bone formed but also the
location of bone on the
scaffold.
This helped identify if the
bone was formed due to
osteoconduction alone or
as a result of osteo
conduction with de novo
bone sytnthesis.
(2) Demonstarted the
donor donor variation with
hMSCs
Radiology
Biopsy
5 patients had no
new bone
K.
Mesimaki
2009
Adipose
tissue
β-TCP 1
Maxillary
reconstruction
(1) First clinical study to
use autologous MSCs
derived from adipose tissue
and expanded employing
good manufacturing
protocols (GMP) to heal a
bone defect.
(2) Use of rhBMP-2 to
promote bone formation in
vivo.
(3) Use of a microvascular
flap reconstruction surgery
for bone tissue engineering
Radiology
biopsy
8-month followup
indicated presence
of mature bone. No
quantification of the
amount of bone
formed is provided.
Good clinical course
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Table 1: Continued.
Principal
investigator
Year
Cell
source
Scaffold Patients
Area of
reconstruction
Salient features Evaluation Reported outcome
Jun Lee 2010
Bone
marrow
Freeze dried
Autologous
cancellous
bone
1
Mandible
reconstruction
(1) Repair of a large
segmental defect (15 cm)
(2) Injection of MSCs with
fibrin glue into the defect
site.
(3) Use of autologous
cancellous freeze dried
bone as a tray to hold the
MSCs in place.
Biopsy
radiology
New bone formation
after 4 months.
No quantification
provided.
Goo clinical
recovery
5
6
7
8
9
10
Figure 5: Overview for patients 5–10 from the study by Meijer et al. to reconstruct a maxillary defect and placement of dental implants. First
column; radiographs showing the alveolar defects. Second column; showing the reconstruction (arrow) by augmentation (5–8) and by sinus
elevation procedure (9 and 10). Third column; radiographs showing the dental implants and the prosthetic construction (crown or bridge).
Fourth column; clinical situation at the end of the rehabilitations (arrow).
Stem Cells International 9
Human MSC
1mm
(a)
Rat MSC
400 µm
(b)
Figure 6: Representative section of scaffold seeded with human bone marrow compared to that seeded with rat bone marrow. Calcium
phosphate ceramic scaffolds were seeded with equal number of cells derived from either human or rat bone marrow and implanted
subcutaneously in nude mice for 6 weeks. Almost all the pores of the scaffold seeded with rat cells are filled with newly formed bone
while the pores of the scaffold seeded with human cells have only one pore with a small amount of bone while the rest of the pores are filled
with fibrous tissue. The sections are stained with basic fuschin and methylene blue. The newly formed bone is stained red with basic fuschin
(black arrows) while the remaining fibrous tissue is stained pink (white arrows). The black areas represent the scaffold.
application. This type of study design can thus provide
conclusive evidence on the efficacy of the new treatment
method as compared to the established standard treatment
option. When possible, the two types of implants should be
implanted in the same patient. A possible situation when this
can be performed without raising ethical issues is when a
patient with bilateral defects needs quantities of autologous
bone graft which may be difficult to obtain without putting
the patient at high risk of complications and morbidity. In
such cases, the autograft can be used to treat one defect while
the other defect is treated simultaneously with the TEC.
Objective evaluation methods should be used to deter-
mine the amount of new bone formed. The sample size
of the patients should be large enough to allow statistical
analysis of the data obtained. We also recommend choice of
a surgical site or a tissue-engineered scaffold which allows
quantification of bone-tissue formation without added
inconvenience to the patient. For instance, we implanted
tissue-engineered grafts in the jaw, where we were able to
obtain a biopsy in the routine course of the procedure.
Other possibilities include tissue-engineered grafts where
MRI, microCT or other noninvasive imaging strategies can
be applied to quantify bone formation.
In all the clinical studies described, culture-expanded
MSCs have been combined with a scaffolding material to
generate TECs. Expansion of hMSCs can have unfavor-
able effects on their differentiation potential [64, 65]. For
instance, Banfi et al. demonstrated that as early as after
the first passage, the bone forming potential was reduced
by about 36 times as compared to fresh marrow [66].
Future studies should employ methods to generate TECs
which completely bypass the expansion phase of MSCs on
plastic. Studies by Warnke et al. [67], Wongchuensoon-
torn et al. [68] Gan et al. [69], and Aslan et al. [70]
have already demonstrated the feasibility of seeding either
mononuclear or enriched populations of MSCs obtained on
scaffold material for enhancing the osteogenic potential of
the cells.
4. Concluding Remarks
Bone-tissue engineering may alleviate problems associated
with the current standard treatment used to heal bone
defects. However, the success with TECs generated using
human MSCs is currently limited. In the majority of the
cases, the human MSCs fail to produce clinically relevant
amounts of bone while MSCs from other species con-
vincingly generate sufficient bone volume (Figure 6). It is
therefore necessary to identify donors with good osteogenic
potential and invest research efforts in improving the bone
forming capacity of the obtained hMSCs to the level of those
obtained from the other species using the widely available
ectopic mouse models before embarking on future clinical
studies.
Identification of a donor having cells with good
osteogenic potential still poses amajor hurdle for bone-tissue
engineering. So far, no literature evidence of a positive
correlation between hMSC osteogenesis in vitro and bone-
formation in vivo has been reported [71]. Our group isolated
hMSCs from 62 donors and assessed the in vitro lineage
differentiation capacity with gene expression signature and
in vivo bone forming capacity. We are currently investigating
a gene which we believe could be used as a reliable diagnostic
marker for in vivo bone-forming capacity (unpublished
data).
This is especially attractive as the knowledge that MSCs
lack certain surface markers responsible for the host T-cell
response opens up possibilities for using such allogeneic cells
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with proven bone forming potential [72, 73]. In addition
to being a ready source of guaranteed bone-forming cells
the patient would also have the benefit of not having to
undergo immunosuppressive therapy. Moreover, combining
allogeneic cells with scaffolds would then make it possible
to have a standardized off the shelf bone-tissue engineering
product which then can be routinely applied to the clinic.
Other areas of preclinical research focus should include
identification of more potent subfractions of hMSCs, in vitro
and in vivo studies with MSCs isolated from “waste” tissues
such as umbilical cord, human placenta, amniotic fluid, and
aborted fetuses, alternative seeding strategies to avoid the
unphysiological expansion of MSCs on plastic and genetic
manipulations ofMSCs [74–76] to enhance the expression of
osteogenic genes and priming of MSCs using growth factors
such as BMPs [77–79] or compounds such as cAMP [43] or
vitamin D [80] to enhance the bone-forming capacity while
maintaining acceptable costs and safety profile. When the
stage is set again for clinical studies, attempts should bemade
to optimize the experimental design. With the imminent
need for bone graft substitutes and the good results obtained
with animal-derived MSCs, bone-tissue engineering using
human MSCs is likely to reenter the clinic once their
biological performance is enhanced.
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